Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

First International Summit on Interventional Pharmacoeconomics

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Varsha Gandhi, PhD, on Ibrutinib

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Opportunities to Optimize Cancer Policies Panel Discussion

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Jul

Today In Oncology

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Related Videos

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Varsha Gandhi, PhD, on Ibrutinib

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Opportunities to Optimize Cancer Policies Panel Discussion

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Breast Cancer: Tailoring Radiotherapy Based on Nodal Response to Primary Chemotherapy

Novel Gene Therapy–Radiotherapy Combination in Localized Prostate Cancer

Advanced Breast Cancer Novel CDK4/6 Inhibitor Plus an Aromatase Inhibitor

Emergency Hospital Admission Accounts for 40 of Ovarian Cancer Diagnoses in England

Perioperative Systemic Therapy vs Surgery Alone in Colorectal Peritoneal-Only Metastases